上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2022 , Vol. 42 >Issue 2: 150 - 157

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.02.003

论著 · 基础研究

Pcsk9基因干扰对高脂诱导的大鼠非酒精性脂肪性肝病合并动脉粥样硬化的影响

  • 张晓文 ,
  • 王祎 ,
  • 张婵 ,
  • 张迪 ,
  • 贠航 ,
  • 黄笛
展开
  • 1.商洛学院健康管理学院护理系，商洛 726000
    2.陕西“四主体一联合”秦岭健康食品配料及核桃产业技术校企联合研究中心，商洛 726000
张晓文（1980—），女，副教授，硕士；电子信箱：zhangxiaowen0728@sina.com。
张晓文，电子信箱：zhangxiaowen0728@sina.com。

收稿日期: 2021-12-14

  网络出版日期: 2022-03-17

基金资助

陕西省科技厅2021年科技计划项目(2021SF-326)

收起

Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats

  • Xiaowen ZHANG ,
  • Yi WANG ,
  • Chan ZHANG ,
  • Di ZHANG ,
  • Hang YUN ,
  • Di HUANG
Expand
  • 1.Department of Nursing, School of Health Management, Shangluo University, Shangluo 726000, China
    2.Shaanxi "Four Subjects and One Union" Qinling Health Food Ingredients and Walnut Industry Technology School-Enterprise Joint Research Center, Shangluo 726000, China
ZHANG Xiaowen, E-mail: zhangxiaowen0728@sina.com.

Received date: 2021-12-14

  Online published: 2022-03-17

Supported by

Shaanxi Provincial Department of Science and Technology 2021 Science and Technology Project(2021SF-326)

Fold

摘要

目的·探讨前蛋白转化酶枯草溶菌素9（proprotein convertase subtilisin kexin 9，Pcsk9）基因干扰对高脂诱导的大鼠非酒精性脂肪性肝病及动脉粥样硬化损伤的影响。方法·构建非酒精性脂肪性肝病SD大鼠模型。40只大鼠随机分为4组：对照组、模型（high fat）组、shRNA-阴性对照（negative control，NC）干扰模型（high fat＋shRNA-NC）组及Pcsk9-shRNA干扰模型（high fat＋Pcsk9-shRNA）组。实时荧光定量聚合酶链反应（real-time quantitative polymerase chain reaction，RT-qPCR）检测Pcsk9基因干扰效率。放射免疫法测定空腹血清胰岛素。全自动生化分析仪检测大鼠血脂指标。苏木精-伊红染色（hematoxylin-eosin staining，H-E染色）观察肝脏组织及主动脉组织损伤。TUNEL染色检测肝脏组织细胞凋亡情况。酶联免疫吸附试验（enzyme linked immunosorbent assay，ELISA）检测外周血中白细胞介素-1β（interleukin-1β，IL-1β）、IL-6及诱导型一氧化氮合酶（inducible nitric oxide synthase，iNOS）的表达水平。蛋白印迹法检测PCSK9、Toll样受体4（Toll-like receptor 4，TLR4）、核因子κB（nuclear factor κB，NF-κB）P65及肿瘤坏死因子α（tumor necrosis factor α，TNF-α）的表达。结果·与对照组比较，模型组的肥胖指数和胰岛素水平显著升高（均P=0.000）；肝脏细胞凋亡率显著升高（P=0.000）；高密度脂蛋白胆固醇（high density lipoprotein cholesterol，HDL-C）水平显著降低，而低密度脂蛋白胆固醇（low density lipoprotein cholesterol，LDL-C）、总胆固醇（total cholesterol，TC）和三酰甘油（triacylglycerol，TAG）水平显著升高（均P=0.000）；炎症因子IL-1β、IL-6、iNOS水平均显著升高（均P=0.000）；TLR4、NF-κB P65蛋白活化及TNF-α表达均显著升高（均P=0.000）；肝脏组织和主动脉组织均呈现明显损伤。干扰Pcsk9基因表达后，与模型组比较，high fat＋Pcsk9-shRNA 组肥胖指数和胰岛素水平显著降低（P=0.007，P=0.000）；肝脏细胞凋亡率显著降低（P=0.000）；HDL-C水平显著升高，而LDL-C、TC和TAG水平显著降低（均P=0.000）；炎症因子IL-1β、IL-6及iNOS水平均显著降低（均P=0.000）；TLR4、NF-κB P65蛋白活化及TNF-α表达均显著降低（均P=0.000）；肝脏组织和主动脉组织病理损伤均得到改善。结论·干扰Pcsk9基因可减轻非酒精性脂肪性肝病合并动脉粥样硬化大鼠的肥胖指数、胰岛素水平、血脂指标及炎症反应，并抑制TLR4、NF-κB P65蛋白激活，进而改善大鼠肝脏及主动脉组织的损伤。

关键词： 前蛋白转化酶枯草溶菌素9; 基因干扰; 非酒精性脂肪性肝病; 动脉粥样硬化; 炎症因子

本文引用格式

张晓文 , 王祎 , 张婵 , 张迪 , 贠航 , 黄笛 . Pcsk9基因干扰对高脂诱导的大鼠非酒精性脂肪性肝病合并动脉粥样硬化的影响[J]. 上海交通大学学报（医学版）, 2022 , 42(2) : 150 -157 . DOI: 10.3969/j.issn.1674-8115.2022.02.003

Abstract

Objective

·To investigate the effects of proprotein convertase subtilisin kexin 9 (Pcsk9) gene knockdown on non-alcoholic fatty liver disease (NAFLD) and atherosclerotic lesions in rats induced by high fat.

Methods

·The SD rat model of NAFLD was established. Rats were randomly divided into 4 groups: control group, model group (high fat), shRNA-negative control (NC) interference model group (high fat+shRNA-NC) and Pcsk9-shRNA interference model group (high fat+ Pcsk9-shRNA). Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect Pcsk9 gene interference efficiency. Fasting serum insulin was determined by radioimmunoassay. Automatic biochemical analyzer was used to detect levels of blood lipid in rats. Hematoxylin-eosin staining (H-E staining) was used to observe the injury of liver tissue and aorta tissue. Apoptosis of liver tissue was detected by TUNEL staining. The levels of interleukin-1β (IL-1β), IL-6 and inducible nitric oxide synthase (iNOS) in peripheral blood were detected by enzyme linked immunosorbent assay (ELISA). The expression of PCSK9, Toll-like receptor 4 (TLR4), nuclear factor κB (NF-κB) P65 and tumor necrosis factor α (TNF-α) were detected by Western blotting.

Results

·Compared with the control group, obesity index and insulin level in the model group were significantly increased (all P=0.000); the apoptosis rate of liver cells was significantly increased (P=0.000); the level of high density lipoprotein cholesterol (HDL-C) was significantly decreased, while the levels of low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triacylglycerol (TAG) were significantly increased (all P=0.000); the levels of IL-1β, IL-6 and iNOS were significantly increased (all P=0.000); TLR4, NF-κB P65 protein activation and TNF-α expression were significantly increased (all P=0.000); the liver tissue and aorta tissue were significantly damaged. After interferenceof Pcsk9 gene expression, compared with the model group, obesity index and insulin level in the high fat＋Pcsk9-shRNA group were significantly reduced (P=0.007, P=0.000); the apoptosis rate of liver cells was significantly reduced (P=0.000); the level of HDL-C was significantly increased while the levels of LDL-C, TC and TAG were significantly decreased (all P=0.000); the levels of IL-1β, IL-6 and iNOS were significantly decreased (all P=0.000); TLR4, NF-κB P65 protein activation and TNF-α expression were significantly decreased (all P=0.000); the histopathological lesions of liver tissue and aorta tissue were improved.

Conclusion

·Knockdown of Pcsk9 gene can reduce obesity index, insulin level, blood lipid index and inflammatory response in the rats with NAFLD and atherosclerosis, and inhibit the activation of TLR4 and NF-κB P65 protein, thereby improving the injury of liver and aortic tissue in rats.

Key words： proprotein convertase subtilisin kexin 9 (Pcsk9); gene interference; non-alcoholic fatty liver disease (NAFLD); atherosclerosis; inflammatory cytokine

参考文献

1 HAN Y M, LEE Y J, JANG Y N, et al. Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARδ-AMPK-PGC-1α pathway in dyslipidemic conditions[J]. Biomed Res Int, 2020, 2020: 7806860.
2 GRATTAGLIANO I, DI CIAULA A, BAJ J, et al. Protocols for mitochondria as the target of pharmacological therapy in the context of nonalcoholic fatty liver disease (NAFLD)[J]. Methods Mol Biol, 2021, 2310: 201-246.
3 YOUNOSSI Z, ANSTEE Q M, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
4 刘艳如, 温晓华, 高冕, 等. 非肥胖人群血浆致动脉硬化指数与非酒精性脂肪性肝病的相关性[J]. 临床误诊误治, 2021, 34(10): 94-98.
5 CAI J, ZHANG X J, JI Y X, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases[J]. Circ Res, 2020, 126(5): 679-704.
6 SCICALI R, DI PINO A, URBANO F, et al. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience[J]. Nutr Metab Cardiovasc Dis, 2021, 31(3): 869-879.
7 马春艳, 徐瑞霞, 姚雨宏, 等. 冠心病患者血浆PCSK9水平与低密度脂蛋白亚组分的相关性研究[J]. 中国分子心脏病学杂志, 2017, 17(4): 2167-2170.
8 THEOCHARIDOU E, PAPADEMETRIOU M, REKLOU A, et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors[J]. Curr Pharm Des, 2018, 24(31): 3654-3657.
9 耿妍, 鲁晓岚, 耿燕, 等. 肠道菌群紊乱在大鼠非酒精性脂肪肝中的作用机制[J]. 分子诊断与治疗杂志, 2020, 12(12): 1626-1630.
10 李滨, 张佳圆, 王凤永, 等. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响[J]. 解放军医药杂志, 2018, 30(10): 93-96.
11 DEMERS A, SAMAMI S, LAUZIER B, et al. Pcsk9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver [J]. Arterioscler Thromb Vasc Biol, 2015, 35(12): 2517-2525.
12 LEBEAU P F, BYUN J H, PLATKO K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice[J]. JHEP Rep, 2019, 1(6): 418-429.
13 王娟, 娜丽, 张迎军, 等. 血清TLR4、HMGB1、IL-6与非酒精性脂肪性肝病患者动脉粥样硬化的相关性[J]. 中西医结合肝病杂志, 2021, 31(8): 712-714.
14 LI M, XU C, SHI J, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway[J]. Gut, 2018, 67(12): 2169-2180.
15 DEWIDAR B, KAHL S, PAFILI K, et al. Metabolic liver disease in diabetes-from mechanisms to clinical trials[J]. Metabolism, 2020, 111S: 154299.
16 PEDERSEN J S, RYGG M O, KRISTIANSEN V B, et al. Nonalcoholic fatty liver disease impairs the liver-alpha cell axis independent of hepatic inflammation and fibrosis[J]. Hepatol Commun, 2020, 4(11): 1610-1623.
17 MUHAMMAD T, IKRAM M, ULLAH R, et al. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling[J]. Nutrients, 2019, 11(3): 648.
18 CHEN M, XING J, PAN D, et al. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway[J]. Biomed Pharmacother, 2020, 128: 110286.
Options
文章导航

/

〈 〉